Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma

@inproceedings{Mahaweni2013TumourderivedEA,
  title={Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma},
  author={Niken M. Mahaweni and Margaretha E. H. Kaijen-Lambers and Jacqueline S Dekkers and Joachim G. J. V. Aerts and Joost P.J.J. Hegmans},
  booktitle={Journal of extracellular vesicles},
  year={2013}
}
BACKGROUND In 2001, it was postulated that tumour-derived exosomes could be a potent source of tumour-associated antigens (TAA). Since then, much knowledge is gained on their role in tumorigenesis but only very recently tumour-derived exosomes were used in dendritic cell (DC)-based immunotherapy. For this, DCs were cultured ex-vivo and loaded with exosomes derived from immunogenic tumours such as melanoma or glioma and re-administrated to induce anti-tumour responses in primary and metastatic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis

  • Lee E-Y, Park K-S, YJ Yoon, J Lee, Moon H-G, SC Jang
  • PLoS One
  • 2012

Similar Papers

Loading similar papers…